By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Jazz Pharmaceuticals 

Corporate Headquarters
Fourth Floor, Connaught House

One Burlington Road
Dublin    4  Ireland
Phone: 353-1-634-7800 Fax: 353-1-634-7850


Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in therapeutic areas where we can meaningfully address serious medical needs.

As part of our unwavering commitment to improve patients’ lives, we continue to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing products in our portfolio; acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and pursuing focused development of a pipeline of post-discovery differentiated product candidates.

Our Culture

We have a strong patient-focused culture at Jazz Pharmaceuticals that our employees believe in and pursue every day. It is clearly identified through our mission, vision and core values. Each member of our team makes integral contributions and is working toward a common goal to improve patients' lives. Everything we do at Jazz Pharmaceuticals is focused on three things:
• Putting patients first
• Being a great place to work
• Living our core values — integrity, collaboration, passion, pursuit of excellence and innovation

Key Statistics

Ownership: Public

Web Site: Jazz Pharmaceuticals
Symbol: JAZZ


Company News
Jazz Pharmaceuticals (JAZZ) Announces Third Quarter 2015 Financial Results 11/10/2015 8:18:33 AM
Jazz Pharmaceuticals (JAZZ) Announces Participation In Three Upcoming Investor Conferences 11/5/2015 10:10:34 AM
Jazz Pharmaceuticals (JAZZ) To Report 2015 Third Quarter Financial Results On November 9, 2015 10/26/2015 7:18:18 AM
Jazz Pharmaceuticals (JAZZ) Announces U.S. FDA Acceptance For Filing With Priority Review Of NDA For Defibrotide For Hepatic Veno-Occlusive Disease 9/30/2015 6:42:56 AM
Jazz Pharmaceuticals (JAZZ) Announces Second Quarter 2015 Financial Results 8/6/2015 7:34:23 AM
Jazz Pharmaceuticals (JAZZ) To Report 2015 Second Quarter Financial Results On August 5, 2015 7/23/2015 10:49:18 AM
Jazz Pharmaceuticals (JAZZ) To Present At Cantor Fitzgerald Healthcare Conference On July 8 7/2/2015 7:45:55 AM
Jazz Pharmaceuticals (JAZZ) Release: Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic 6/9/2015 6:30:18 AM
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Clinical Development Program Evaluating JZP-110 As A Potential Treatment Of Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy Or With Obstructive Sleep Apnea (OSA) 6/8/2015 7:18:13 AM
Jazz Pharmaceuticals (JAZZ) To Present Abstracts From Ongoing Evaluations Of Xyrem (Sodium Oxybate) At SLEEP 2015 6/4/2015 8:03:09 AM